中国生物制药在AACR年会上披露两款创新药TQB3002和TQB3019,分别针对肺癌EGFR突变和血液瘤,可抑制多重耐药突变,具有临床开发价值。TQB3002已获NMPA和FDA临床试验许可。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.